Single User License
INR 136740
Site License
INR 273480
Corporate User License
INR 410220

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Glomerulonephritis-Pipeline Review, H1 2015

Glomerulonephritis-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Glomerulonephritis-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Glomerulonephritis-Pipeline Review, H1 2015', provides an overview of the Glomerulonephritis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Glomerulonephritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Glomerulonephritis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Glomerulonephritis

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Glomerulonephritis and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Glomerulonephritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Glomerulonephritis pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Glomerulonephritis

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Glomerulonephritis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Glomerulonephritis Overview 8

Therapeutics Development 9

Pipeline Products for Glomerulonephritis-Overview 9

Pipeline Products for Glomerulonephritis-Comparative Analysis 10

Glomerulonephritis-Therapeutics under Development by Companies 11

Glomerulonephritis-Therapeutics under Investigation by Universities/Institutes 12

Glomerulonephritis-Pipeline Products Glance 13

Late Stage Products 13

Clinical Stage Products 14

Early Stage Products 15

Glomerulonephritis-Products under Development by Companies 16

Glomerulonephritis-Products under Investigation by Universities/Institutes 17

Glomerulonephritis-Companies Involved in Therapeutics Development 18

Adienne Pharma & Biotech 18

Alexion Pharmaceuticals, Inc. 19

Avexxin AS 20

Biogen Idec Inc. 21

ChemoCentryx, Inc. 22

FibroStatin SL 23

GlaxoSmithKline plc 24

Hansa Medical AB 25

Mallinckrodt plc 26

New Zealand Pharmaceuticals Limited 27

Pharmalink AB 28

Toray Industries, Inc. 29

Glomerulonephritis-Therapeutics Assessment 30

Assessment by Monotherapy Products 30

Assessment by Target 31

Assessment by Mechanism of Action 33

Assessment by Route of Administration 35

Assessment by Molecule Type 37

Drug Profiles 39

AVX-235-Drug Profile 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

belimumab-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

budesonide-Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

CCX-168-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

corticotropin-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

DEXM-74-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

Drug to Inhibit GPBP for Glomerulonephritis and Cancer-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

eculizumab-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

Endoglycosidase of Streptococcus pyogenes-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

Mubodina-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

Peptide to Inhibit ETA and ETB for Rapidly Progressive Glomerulonephritis-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

rituximab-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

Small Molecule to Inhibit Vitamin K Epoxide Reductase for Glomerulonephritis-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

Glomerulonephritis-Recent Pipeline Updates 62

Glomerulonephritis-Dormant Projects 76

Glomerulonephritis-Discontinued Products 77

Glomerulonephritis-Product Development Milestones 78

Featured News & Press Releases 78

Oct 31, 2012: Pharmalink Signs Manufacturing Agreement For Nefecon 78

Sep 09, 2011: Adienne Pharma Receives EMA's Positive Opinion For Orphan Drug Designation For Recombinant Human Minibody Mubodina 78

Oct 13, 2010: Pharmalink Receives US Orphan Drug Designation For Nefecon 78

Oct 26, 2009: Japanese Patent granted for Pharmalink AB's Nefecon 79

Apr 29, 2009: Pharmalink AB Completes Phase II Clinical Study With Renal Disease Drug Nefecon 79

Mar 31, 2008: Pharmalink Reports Promising Interim Results From Phase II Trials For New Renal Disease Drug Nefecon 80

Appendix 81

Methodology 81

Coverage 81

Secondary Research 81

Primary Research 81

Expert Panel Validation 81

Contact Us 81

Disclaimer 82

List of Tables

Number of Products under Development for Glomerulonephritis, H1 2015 9

Number of Products under Development for Glomerulonephritis-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 11

Number of Products under Investigation by Universities/Institutes, H1 2015 12

Comparative Analysis by Late Stage Development, H1 2015 13

Comparative Analysis by Clinical Stage Development, H1 2015 14

Comparative Analysis by Early Stage Development, H1 2015 15

Products under Development by Companies, H1 2015 16

Products under Investigation by Universities/Institutes, H1 2015 17

Glomerulonephritis-Pipeline by Adienne Pharma & Biotech, H1 2015 18

Glomerulonephritis-Pipeline by Alexion Pharmaceuticals, Inc., H1 2015 19

Glomerulonephritis-Pipeline by Avexxin AS, H1 2015 20

Glomerulonephritis-Pipeline by Biogen Idec Inc., H1 2015 21

Glomerulonephritis-Pipeline by ChemoCentryx, Inc., H1 2015 22

Glomerulonephritis-Pipeline by FibroStatin SL, H1 2015 23

Glomerulonephritis-Pipeline by GlaxoSmithKline plc, H1 2015 24

Glomerulonephritis-Pipeline by Hansa Medical AB, H1 2015 25

Glomerulonephritis-Pipeline by Mallinckrodt plc, H1 2015 26

Glomerulonephritis-Pipeline by New Zealand Pharmaceuticals Limited, H1 2015 27

Glomerulonephritis-Pipeline by Pharmalink AB, H1 2015 28

Glomerulonephritis-Pipeline by Toray Industries, Inc., H1 2015 29

Assessment by Monotherapy Products, H1 2015 30

Number of Products by Stage and Target, H1 2015 32

Number of Products by Stage and Mechanism of Action, H1 2015 34

Number of Products by Stage and Route of Administration, H1 2015 36

Number of Products by Stage and Molecule Type, H1 2015 38

Glomerulonephritis Therapeutics-Recent Pipeline Updates, H1 2015 62

Glomerulonephritis-Dormant Projects, H1 2015 76

Glomerulonephritis-Discontinued Products, H1 2015 77

List of Figures

Number of Products under Development for Glomerulonephritis, H1 2015 9

Number of Products under Development for Glomerulonephritis-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 11

Comparative Analysis by Early Stage Products, H1 2015 15

Assessment by Monotherapy Products, H1 2015 30

Number of Products by Top 10 Targets, H1 2015 31

Number of Products by Stage and Top 10 Targets, H1 2015 31

Number of Products by Top 10 Mechanism of Actions, H1 2015 33

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 34

Number of Products by Top 10 Routes of Administration, H1 2015 35

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 36

Number of Products by Top 10 Molecule Types, H1 2015 37

Number of Products by Stage and Top 10 Molecule Types, H1 2015 38

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Adienne Pharma & Biotech

Alexion Pharmaceuticals, Inc.

Avexxin AS

Biogen Idec Inc.

ChemoCentryx, Inc.

FibroStatin SL

GlaxoSmithKline plc

Hansa Medical AB

Mallinckrodt plc

New Zealand Pharmaceuticals Limited

Pharmalink AB

Toray Industries, Inc.

Glomerulonephritis Therapeutic Products under Development, Key Players in Glomerulonephritis Therapeutics, Glomerulonephritis Pipeline Overview, Glomerulonephritis Pipeline, Glomerulonephritis Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com